ArticleActa parasitologica2025
In Vitro and in Vivo Therapeutic Evaluation of Ethanolic Extract of Sumac and Compounds of Linalool and Eugenol Against Localized Cutaneous Leishmaniasis Induced by Leishmania major.
Article in Acta parasitologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCutaneous leishmaniasis remains a significant public health problem and continues to pose a substantial challenge to the healthcare system. First-line drugs, particularly pentavalent compounds, are used to treat this disease. The increasing drug resistance, the reduced efficacy of current therapies, and the high treatment costs. Have shifted the focus of research toward herbal remedies and natural products. This study sought to examine the possible antileishmanial properties of the ethanolic extract from R. coriaria and compounds of linalool and eugenol, both in vitro and in vivo against skin lesions caused by L. major in BALB/c mice.
methodsThe CC50 toxicity and IC50 anti-leishmanial effect of linalool and eugenol were examined on the macrophage cell line and promastigotes. In the in vivo phase, a total of 54 mice were infected with L. major and treated. Three weeks after the end of treatment, parasitological and molecular examinations were performed using real-time PCR.
resultsAn in vitro study showed that linalool and eugenol had favorable lethality and toxicity values and were significantly correlated with the control group. According to the results of this study, the healing rates of lesions in the high-dose eugenol, low-dose linalool, and Glucantime® groups was 90.6%, 89.01%, and 85.58%, respectively. The results of the evaluations showed that the parasite load in the treated groups was significantly reduced. The reduction of specific KDNA gene expression and parasite load in the liver and spleen organs showed the degree of improvement and efficacy of the extract and compounds in real-time PCR.
conclusionThis study demonstrates that the alcoholic extract of sumac and compounds of linalool and eugenol are effective in the treatment of cutaneous leishmaniasis and offers a promising perspective for the development of herbal medicines with fewer side effects.
Indexed as
Identifiers
41400844What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.